SEC Form 4 · accession 0001734780-26-000004

Nuvation Bio Inc. · NUVB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CHIEF PEOPLE OFFICER

Period of report

Jun 23, 2026

Accepted (ET)

Jun 24, 2026 · 7:09 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001811063

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Class A Common Stock	Jun 23, 2026	M	90,380	$1.87	A	122,971	D
Class A Common Stock	Jun 23, 2026	M	34,620	$1.74	A	157,591	D
Class A Common Stock^F2	Jun 23, 2026	S	125,000	$6.0255	D	32,591	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$1.87	Jun 23, 2026	M	90,380	D	—	Feb 27, 2034	Class A Common Stock	90,380	409,620	D
Stock Option (Right to Buy)^F4	$1.74	Jun 23, 2026	M	34,620	D	—	Jan 21, 2030	Class A Common Stock	34,620	220,190	D

F1Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
F2Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.085. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
F4Option vests as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years, subject to Reporting Person's continuous service on each such vesting date.